Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First patient exceeding 5-year complete remission after 225Ac-PSMA-TAT.
Rathke H, Bruchertseifer F, Kratochwil C, Keller H, Giesel FL, Apostolidis C, Haberkorn U, Morgenstern A. Rathke H, et al. Among authors: morgenstern a. Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):311-312. doi: 10.1007/s00259-020-04875-y. Epub 2020 May 28. Eur J Nucl Med Mol Imaging. 2021. PMID: 32468252 No abstract available.
Determination of the age of highly enriched uranium.
Wallenius M, Morgenstern A, Apostolidis C, Mayer K. Wallenius M, et al. Among authors: morgenstern a. Anal Bioanal Chem. 2002 Oct;374(3):379-84. doi: 10.1007/s00216-002-1555-9. Epub 2002 Sep 10. Anal Bioanal Chem. 2002. PMID: 12373381
Cyclotron production of Ac-225 for targeted alpha therapy.
Apostolidis C, Molinet R, McGinley J, Abbas K, Möllenbeck J, Morgenstern A. Apostolidis C, et al. Among authors: morgenstern a. Appl Radiat Isot. 2005 Mar;62(3):383-7. doi: 10.1016/j.apradiso.2004.06.013. Appl Radiat Isot. 2005. PMID: 15607913
Non-invasive visualisation of the development of peritoneal carcinomatosis and tumour regression after 213Bi-radioimmunotherapy using bioluminescence imaging.
Buchhorn HM, Seidl C, Beck R, Saur D, Apostolidis C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Buchhorn HM, et al. Among authors: morgenstern a. Eur J Nucl Med Mol Imaging. 2007 Jun;34(6):841-9. doi: 10.1007/s00259-006-0311-3. Epub 2007 Jan 6. Eur J Nucl Med Mol Imaging. 2007. PMID: 17206415
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.
Knör S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, Kessler H, Senekowitsch-Schmidtke R, Magdolen V, Seidl C. Knör S, et al. Among authors: morgenstern a. Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):53-64. doi: 10.1007/s00259-007-0582-3. Epub 2007 Sep 22. Eur J Nucl Med Mol Imaging. 2008. PMID: 17891393
279 results